Can preserved ovaries after hysterectomy still have reduced hormone output, and is MCM8 rs16991615 GG linked to earlier reproductive aging?

Both surgical interventions and genetic variations play major roles in accelerating the timeline of ovarian senescence. Understanding these factors provides critical insights into the endocrine trajectories of reproductive aging.

Clinical evidence of ovarian decline

• Impact of Hysterectomy: Preserving the ovaries during a hysterectomy does not guarantee long-term endocrine stability. Prospective cohort studies show that women with preserved ovaries experience menopause 1.5 to 4 years earlier than age-matched controls with an intact uterus.
• Endocrine Biomarkers: Within five years post-surgery, there is a nearly twofold risk of ovarian failure, characterized by follicle-stimulating hormone (FSH) levels $\ge$ 40 IU/L, alongside significant declines in anti-Müllerian hormone (AMH) and inhibin B, which ultimately leads to reduced estradiol and progesterone output.

Mechanistic pathways of accelerated aging

• Vascular Disruption: Surgical hysterectomy often alters or reduces ovarian perfusion by disrupting the uterine-ovarian arterial branches. This diminished blood flow compromises ovarian function, accelerating follicular atresia and reducing sex steroid production.
• Genetic DNA Repair Deficits: The MCM8 gene is essential for repairing double-strand DNA breaks via homologous recombination, maintaining oocyte genomic integrity. The missense SNP rs16991615 (GG variant) acts as a quantitative modifier that shifts the onset of natural menopause earlier by approximately 0.7 to 1 year per risk allele.

Bottom line

• Surgical disruption of uterine-ovarian blood flow post-hysterectomy and the inheritance of the MCM8 rs16991615 GG genetic variant both significantly accelerate the decline of ovarian reserve, resulting in an earlier-than-expected loss of estrogen and progesterone production.